首页 > 市场调查报告书 > 医疗设备

医学影像诊断癌症个人化医学分子呈像/呈影剂核子医学

市场调查报告书

商品编码

1316304

全球 Theranostics 市场 - 2023-2030 年

Global Theranostics Market - 2023-2030

出版日期: 2023年07月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概述

全球治疗仪市场规模在 2022 年达到 18 亿美元，预计到 2030 年将实现利润丰厚的增长，达到 42 亿美元。在预测期内（2023-2030 年），全球治疗仪市场将呈现 11.3% 的复合年增长率。

Theranostics 是治疗和诊断两个术语的组合。治疗学是指使用一种放射性药物进行识别（诊断），并使用第二种放射性药物进行治疗，以治疗主要肿瘤和任何转移性肿瘤。这些检测主要用于各种形式的癌症。治疗学的主要关注点是借助更加个性化和精确的方法，提供以患者为中心的护理。

全球治疗学市场的最新趋势包括：纳米药物因其成像功能而被广泛采用，并被整合成一个单一的实体，即纳米otheranostics，它将诊断和药物治疗结合在一起。此外，人们对使用聚集诱导发光发光剂进行细菌治疗的兴趣也在不断增长。

制药公司、研究机构和医疗保健提供商对该市场的投资和合作不断增加。这主要得益于对提供个性化和靶向治疗的治疗仪需求的不断增长。此外，在整个预测期内，治疗仪领域正在进行的研究工作、临床试验数量的增加以及旨在提高认识和促进进步的会议数量的增加预计将成为主要的推动因素。

市场动态

用于治疗癌症的放射性核素治疗技术研究会议的增加将推动全球治疗技术市场的增长

根据《2022 年戈登研究会议》，会议将探讨放射性核素治疗癌症的最新进展和影响。会议旨在促进来自学术界、私人诊所和行业等不同领域的科学家、医生和专家等杰出演讲者之间的正式和非正式互动与合作。会议的主要科学目标是应对放射性核素治疗学的相关挑战，鼓励在癌症研究方面取得重大突破。

会议形式独特，其特点是规模小、环境幽静、数据未公开发表、讨论时间充裕，为有意义的互动与合作提供了难得的机会，很可能对该领域产生重大而持久的影响。利用放射性核素成像和治疗的精准肿瘤学正处于创新和显著增长的变革阶段，因此本次会议意义尤为重大。

它提供了比以往任何时候都更精确的诊断和个性化有效抗肿瘤治疗的潜力。此外，越来越多的大型制药公司参与进来，放射治疗领域也涌现出 50 多家新公司，这些都证明了这一点。

此外，利用β、α或γ放射性核素治疗癌症的临床试验数量也在迅速增加。本次会议的时机至关重要，因为它恰逢基于放射性核素的精准肿瘤学即将取得重大进展的关键时刻，标志着该领域的范式转变和前所未有的进步。因此，由于上述因素，市场将在预测期内得到推动。

美国 FDA 批准的癌症治疗方案越来越多，将推动全球血流显像技术市场的增长

2022 年 11 月 29 日，Clarity Pharmaceuticals 公司获得美国食品及药物管理局（FDA）批准，开展治疗前列腺癌的 SAR-Bombesin 临床试验。前列腺癌是导致全球癌症相关死亡的第五大原因，也是第二大最常见的男性癌症。据美国国家癌症研究所（NCI）称，仅在美国，每年就有约 268,490 例前列腺癌病例报告，导致约 34,500 人死亡。

SAR-Bombesin 是一种放射性药物，旨在靶向存在于各类癌症中的特定细胞表面受体。新闻稿强调，胃泌素释放肽受体（GRPr）可在75%-100%的前列腺癌中发现。

SAR-Bombesin 复合物具有多重功效。它的 SAR 成分（也称为 sarcophagine）是一种螯合剂，能安全地封装铜同位素，防止其泄漏到体内。该公司称，SAR-Bombesin 是一种靶向铜治疗药物（TCT），可将铜-64 同位素（Cu-64 或 64Cu）用于成像，将铜-67 同位素（Cu-67 或 67Cu）用于治疗。

同样，2022 年 3 月 23 日，诺华公司的 PluvictoTM（镥-Lu 177 vipivotide tetraxetan）（以前称为 177Lu-PSMA-617）获得了美国食品及药物管理局的批准。这项批准允许 Pluvicto 用于治疗患有前列腺特异性膜抗原阳性（PSMA 阳性）肿瘤并已扩散到身体其他部位的转移性抗性前列腺癌（mCRPC）成人患者。这些患者已经接受了其他抗癌治疗，如雄激素受体通路抑制和基于类固醇的化疗。

此外，FDA 还批准了 Locametz（镓 Ga 68 戈氮卓肽注射液的制备试剂盒）。经过放射性标记后，这种成像剂可用于mCRPC成年患者，通过正电子发射断层扫描（PET）确定PSMA阳性病灶。

通过使用镓-68标记的洛卡麦茨，医生可以检测到表达PSMA生物标记物的肿瘤病灶，并确定肿瘤在体内（包括软组织、淋巴结或骨骼）的扩散情况。这有助于确定符合使用普卢维特进行靶向治疗的患者。PSMA在80%以上的前列腺癌患者中高度表达，是评估转移性前列腺癌进展的重要生物标记物。

治疗技术的高成本将阻碍全球治疗技术市场的增长

利用放射性药物的治疗学领域在改善癌症诊断和治疗方面前景广阔。然而，一些最有效的治疗药物依赖于稀有的同位素，这些同位素很难获得，而且将其转化为能够靶向消除癌细胞的药物成本高昂。虽然癌症治疗的进步指日可待，但也不可避免地伴随着高昂的代价。

例如，用于癌症诊断的镥177疗法的费用因国家、医院和主治医生而异。镥 177 治疗的平均费用约为每个疗程 10 000 美元，病人可能需要接受三至四个疗程的治疗。

同样，在印度，Lu177 PSMA 治疗的估计费用通常从 5000 美元起，最高可达 6000 美元。此外，在德国，专科医院使用镥 177 进行 PSMA 治疗的费用在 8000-16000 欧元之间，其中包括初始临床和实验室检查、PSMA 治疗本身、后续检查和住院费用。因此，由于上述因素，市场在预测期内将受到阻碍。

COVID-19 影响分析

受 COVID-19 爆发的影响，治疗仪市场在预测期内将面临初步的挑战和衰退。全国范围的封锁和限制导致诊断服务中断和手术取消，影响了对治疗仪的需求。

疫情尤其影响了肿瘤和心血管疾病患者的治疗，因为这些患者因年龄和合并症而患重病的风险较高。疫情爆发的程度和实施的限制因地区而异，对慢性病患者的影响也不尽相同。

在德国等国家，为防止对医疗系统造成压力，实施了公共封锁和非紧急医疗服务限制。由于 COVID-19 的影响，医疗保健行业的供应链和需求都受到了干扰。

由于公众对去医院就诊的恐惧减缓了对治疗程序的需求，这种程序常用于肿瘤和与肿瘤相关的疾病，因此可帮助降低感染毒性（包括 COVID-19）的治疗程序也受到了影响。不过，随着疫情得到控制，人们适应了新的生活方式，医学专家们一直在研究这种病毒，并探索在治疗中使用治疗仪。

COVID-19 大流行对全球的影响要求我们采取更有效的措施来减少病毒的传播，并开发高效的治疗药物。包括冠状病毒在内的病毒具有高度异质性，这给开发有效的抗病毒药物带来了巨大挑战。病毒的高变异率会对病毒检测、药物和疫苗开发的有效性产生负面影响，甚至导致耐药性。然而，治疗学领域提供了前景广阔的解决方案。

此外，纳米机器人的使用可提供实时的病毒防护，为治疗包括 COVID-19 在内的各种疾病的疗法的重大进展提供了可能性。此外，基于纳米技术的方法不仅彻底改变了传统的消毒程序，还为加速监测冠状病毒及其相关生物标记物提供了分析工具。这些方法有助于将药物输送到呼吸系统或其他受影响的器官。

俄乌冲突分析

俄乌战争对全球地缘政治格局的各个方面都产生了影响，包括对治疗仪市场的潜在影响。在政治不稳定的情况下，俄罗斯、乌克兰和其他国家的机构之间的研发合作可能面临挑战。科研合作的中断可能会减缓治疗仪研究的进展，阻碍新技术和新疗法的开发。

持续的冲突可能会给俄罗斯和乌克兰的医疗保健系统带来额外的压力。由于资源被转用于解决冲突造成的紧急医疗需求，治疗技术研究、基础设施和实施方面的投资和优先事项可能会受到影响。因此，考虑到上述因素，可以说战争对治疗仪市场的影响不大。

GE Healthcare
- 公司概况
- 产品组合和说明
- 财务概况
- 主要发展
Jubilant Pharmova Limited (Jubilant Pharma Limited)
Theragnostics Ltd.
NuView Life Sciences
Lantheus Holdings, Inc.
CapVest Limited (Curium Pharma)
Clarity Pharmaceuticals
Cardinal Health, LLC
Advanced Accelerator Applications
ITM Isotopen Technologien Munchen AG

第 14 章：附录

简介目录

Product Code: BT1187

Market Overview

The global theranostics market reached US$ 1.8 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 4.2 billion by 2030. The global theranostics market is to exhibit a CAGR of 11.3% during the forecast period (2023-2030).

Theranostics is a combination of the terms therapeutics and diagnostics. Theranostics is the term used to describe the combination of using one radioactive drug to identify (diagnose) and a second radioactive drug to deliver therapy to treat the main tumor and any metastatic tumors. These tests are mainly used for various forms of cancers. The key concern in therapeutics involves patient-centric care with the help of a more personalized and precise approach.

Recent trends in the global theranostics market include the widespread adoption of nanomedicines for their imaging capabilities and their integration into a single entity known as nanotheranostics, which combines diagnosis and drug therapy. Additionally, there is a growing interest in using aggregation-induced emissive luminogens for bacterial theranostics.

The market is witnessing rising investment and collaborations among pharmaceutical companies, research institutions, and healthcare providers. This is driven by the increasing demand for theranostics, which offer personalized and targeted treatments. Furthermore, ongoing research endeavors in the field of theranostics, a rise in the number of clinical trials, and the increasing number of conferences aimed at raising awareness and promoting advancements are anticipated to be key driving factors throughout the forecast period.

Market Dynamics

Increasing Research Conferences in Radionuclide Theranostics for the Management of Cancer are to Drive Global Theranostics Market Growth

According to Gordon Research Conference 2022, it will explore the latest advancements and impact of Radionuclide Theranostics in the management of cancer patients. It aims to facilitate formal and informal interactions and collaborations among a distinguished group of speakers, including scientists, physicians, and experts from various sectors such as academia, private practice, and industry. The primary scientific objective of the conference is to address the challenges associated with radionuclide theranostics and encourage significant breakthroughs in cancer research.

The unique format of the conference, characterized by its small size, secluded setting, unpublished data, and ample time for discussion, provides an exceptional opportunity for meaningful interactions and collaborations that are likely to have a substantial and enduring impact on the field. This gathering is particularly significant as precision oncology utilizing radionuclide-based imaging and therapy is experiencing a transformative phase of innovation and remarkable growth.

It offers the potential for more precise diagnostics and personalized and effective anti-tumor treatments than ever before. Moreover, this is evident from the increasing participation of major pharmaceutical companies and the emergence of over 50 new players in the field of radiotheranostics.

Furthermore, the number of clinical trials utilizing beta, alpha, or gamma-emitting radionuclides in cancer treatment is rapidly expanding. The timing of this conference is crucial, as it coincides with the pivotal moment when radionuclide-based precision oncology is poised for significant advancements, signifying a paradigm shift in the field and unprecedented progress. Thus, owing to the above factors, the market is to drive over the forecast period.

Increasing FDA Approvals in Cancer are to Drive Global Theranostics Market Growth

On November 29, 2022, Clarity Pharmaceuticals received approval from the FDA to conduct clinical trials with SAR-Bombesin, a theranostic agent, for the treatment of prostate cancer. Prostate cancer ranks as the fifth leading cause of cancer-related deaths worldwide and is the second most commonly diagnosed cancer in men. In the United States alone, approximately 268,490 cases of prostate cancer are reported annually, resulting in about 34,500 deaths, according to the NCI.

SAR-Bombesin is a radiopharmaceutical designed to target specific cell surface receptors present in various types of cancer. The press release highlights that gastrin-releasing peptide receptors (GRPr) can be found in 75-100% of prostate cancers.

The SAR-Bombesin compound offers multiple benefits. Its SAR component, also known as sarcophagine, acts as a chelator that securely encapsulates copper isotopes, preventing any leakage into the body. The company states SAR-Bombesin is a Targeted Copper Theranostic (TCT) that can utilize copper-64 isotopes (Cu-64 or 64Cu) for imaging purposes and copper-67 isotopes (Cu-67 or 67Cu) for therapeutic applications.

Similarly, on March 23, 2022, Novartis received FDA approval for PluvictoTM (lutetium Lu 177 vipivotide tetraxetan), previously known as 177Lu-PSMA-617. This approval allows Pluvicto to be used in the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have prostate-specific membrane antigen-positive (PSMA-positive) tumors that have spread to other parts of the body. These patients have already undergone other anticancer treatments such as androgen receptor pathway inhibition and taxane-based chemotherapy.

Additionally, the FDA has approved Locametz (kit for the preparation of gallium Ga 68 gozetotide injection). After radiolabeling, this imaging agent can be used in adult patients with mCRPC to identify PSMA-positive lesions through positron emission tomography (PET) scans.

By using Gallium-68 labeled Locametz, physicians can detect tumor lesions expressing the PSMA biomarker and determine the spread of tumors in the body, including soft tissue, lymph nodes, or bone. This helps identify patients eligible for targeted treatment with Pluvicto. PSMA is highly expressed in over 80 percent of patients with prostate cancer, making it a crucial biomarker for assessing the progression of metastatic prostate cancer.

High Cost of Theranostics is to Hamper Global Theranostics Market Growth

The field of theranostics, which utilizes radiopharmaceuticals, holds great promise for improving cancer diagnosis and treatment. However, some of the most effective theranostic agents rely on rare isotopes that are challenging to obtain and costly to convert into drugs capable of targeting and eliminating cancer cells. While advancements in cancer care are shortly, they will inevitably come with a high price tag.

For instance, the cost of Lutetium-177 therapy for cancer diagnosis varies depending on the country, hospital, and treating doctor. The average cost of Lutetium-177 therapy is around $10,000 per course, and a patient may undergo three to four courses.

Similarly, in India, the estimated cost of Lu177 PSMA Therapy usually starts at $5000 and may go up to $6000. Also, in Germany, the cost of PSMA therapy with Lutetium 177 in specialized hospitals ranges between 8000-16,000 euros, which covers the cost of the initial clinical and laboratory examination, the PSMA therapy itself, the follow-up examinations, and the hospital stay. Thus, owing to the above factors, the market is to hamper over the forecast period.

COVID-19 Impact Analysis

The theranostics market is to face initial challenges and decline during the forecast period due to the impact of the COVID-19 outbreak. Nationwide lockdowns and restrictions have led to disrupted diagnostic services and canceled procedures, affecting the demand for theranostics.

The pandemic has particularly affected the care of patients with oncology and cardiovascular diseases, as they are at a higher risk of severe illness due to their age and comorbidities. The extent of the outbreak and the restrictions imposed vary across regions, influencing individuals with chronic diseases differently.

In countries like Germany, efforts were made to prevent strain on the healthcare system, but public lockdowns and limited access to non-urgent medical services were implemented. The healthcare industry has experienced disruptions in supply chains and demand due to COVID-19.

Theranostics, which can assist in reducing the virulence of infections, including COVID-19, have been impacted as the fear of hospital visits among the public has slowed down the demand for theranostic procedures, which are commonly used in oncology and tumor-related conditions. However, as the pandemic is brought under control and people adapt to the new lifestyle, medical experts have been studying the virus and exploring the use of theranostics in its treatment.

The global impact of the COVID-19 pandemic necessitates the implementation of more effective measures to mitigate the spread of the virus and develop efficient theranostic agents. The high heterogeneity of viruses, including the coronavirus, poses a significant challenge in developing effective antiviral agents. The virus's high mutation rates can negatively impact virus detection, the efficacy of drug and vaccine development, and even lead to drug resistance. However, the field of theranostics offers promising solutions.

Additionally, the use of nanorobots provides real-time protection against viruses, opening up possibilities for significant advancements in theranostics for various diseases, including COVID-19. Furthermore, nanotechnology-based approaches not only revolutionize traditional disinfection procedures but also offer analytical tools for accelerated monitoring of the coronavirus and its associated biomarkers. These approaches can facilitate drug delivery to the respiratory system or other affected organs.

Russia-Ukraine Conflict Analysis

The Russian-Ukraine war has had an impact on various aspects of the global geopolitical landscape, including potential implications for the theranostics market. In the face of political instability, research and development collaborations between institutions in Russia, Ukraine, and other countries may face challenges. Disruptions in scientific collaborations could slow down the progress of theranostic research and hinder the development of new technologies and treatments.

The ongoing conflict may place additional strain on the healthcare systems in both Russia and Ukraine. As resources are redirected towards addressing immediate healthcare needs arising from the conflict, investments, and priorities for theranostics research, infrastructure, and implementation may be affected. Therefore, taking into account the factors mentioned earlier, it can be stated that the theranostics market experienced a moderate impact as a result of the war.

Segment Analysis

The global theranostics market is segmented based on application, radioisotopes, end user, and region.

Oncology from the Application Segment Account for 57.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Growing Theranostics Gordon Research Conferences

According to Pan American Health Organization Report 2023, globally, there were an estimated 20 million new cases of cancer and 10 million deaths from cancer. The cancer burden will increase by approximately 60% over the next two decades, further straining health systems, people, and communities. The predicted global burden will increase to about 30 million new cancer cases by 2040, with the greatest increases occurring in low- and middle-income countries.

In the Americas region the, number of people to be diagnosed with cancer will increase by 57%, to approximately 6.23 million people are predicted to be diagnosed with cancer by 2040, if no further action is taken to prevent and control cancer.

Additionally, On June 23, 2023, Cardinal Health Nuclear & Precision Health Solutions (NPHS) will be showcasing their radiotherapies and theranostics readiness at the annual meeting of the Society of Nuclear Medicine & Molecular Imaging (SNMMI) in booth #2041.

Attendees at the Cardinal Health NPHS booth will have the opportunity to learn about the company's reliable access to radiopharmaceuticals and solutions that contribute to safe, efficient, and high-quality patient care. The booth will feature demonstrations of the Nuctrac theranostic module and offer "Ask an Expert" sessions on theranostics and USP <825>, which sets requirements for the preparation, compounding, dispensing, and repackaging of radiopharmaceuticals.

At SNMMI 2023, visitors to Booth #2041 will discover how Cardinal Health NPHS is advancing nuclear medicine through its expertise and comprehensive range of products and services. They are dedicated to improving patient care by enhancing productivity, efficiency, and theranostics practice management solutions. Thus, owing to the above factors, the market segment is to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 43.9% of the Market Share Owing to the Increasing Prevalence of Cancer, Rising FDA Approvals, and Growing Research in Theranostics

The increasing prevalence of cancer, rising FDA approvals, and growing research in theranostics are some factors due to which the market is to boost in the forecast period. For instance, on March 23, 2022, the U.S. FDA approved 177Lu-PSMA-617, a radiopharmaceutical therapy to treat metastatic castration-resistant prostate cancer (mCRPC). In mCRPC patients treated with 177Lu-PSMA-617, the therapy has been shown to reduce the risk of death by 38% and the risk of progression by 60%. It was developed after years of extensive research.

Furthermore, UChicago Medicine is a leader in the development and administration of theranostic procedures. They are actively researching to expand this promising treatment option for other types of cancer. UChicago Medicine is the only hospital in Illinois to have a medical cyclotron, which is a powerful machine capable of manufacturing new kinds of radiotracers. The research team partners with experts at Argonne National Laboratory, an internationally renowned facility that has provided instrumental research on using radiation to treat cancer.

Sophisticated radiotracers consisting of a biological component engineered to latch on to cancer cells and interchangeable radioactive isotopes that can make those cells visible on a PET scan are providing physicians with more tools to fight certain cancers. Theranostics is a one-two punch against cancer that involves finding cancer cells anywhere in the body and delivering targeted radiation to kill those cells. Thus, owing to the above factors, the North American region is to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: GE Healthcare, Jubilant Pharmova Limited (Jubilant Pharma Limited), Theragnostics Ltd., NuView Life Sciences, Lantheus Holdings, Inc., CapVest Limited (Curium Pharma), Clarity Pharmaceuticals, Cardinal Health, LLC, Advanced Accelerator Applications, and ITM Isotopen Technologien Munchen AG among others.

Why Purchase the Report?

To visualize the global theranostics market segmentation based on application, radioisotopes, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of theranostics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global theranostics market report would provide approximately 61 tables, 63 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Application
3.2. Snippet by Radioisotopes
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing Research Conferences in Radionuclide Theranostics for the Management of Cancer
  - 4.1.1.2. Increasing FDA Approvals in Cancer
- 4.1.2. Restraints
  - 4.1.2.1. High Cost of Theranostics Diagnostic
- 4.1.3. Opportunity
  - 4.1.3.1. Fast-Growing Field of Photo-Driven Theranostics
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Oncology*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Neurological Disorder
8.4. Cardiovascular Disease
8.5. Others

9. By Radioisotopes

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Radioisotopes
- 9.1.2. Market Attractiveness Index, By Radioisotopes
9.2. Technetium-99*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Gallium-68
9.4. Lutetium (Lu) 177
9.5. Iodine-131
9.6. Zirconium-89
9.7. Y-90
9.8. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cancer Research Institutes
10.4. Diagnostic Centers
10.5. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. U.K.
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User
- 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
- 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Radioisotopes
- 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. GE Healthcare*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Jubilant Pharmova Limited (Jubilant Pharma Limited)
13.3. Theragnostics Ltd.
13.4. NuView Life Sciences
13.5. Lantheus Holdings, Inc.
13.6. CapVest Limited (Curium Pharma)
13.7. Clarity Pharmaceuticals
13.8. Cardinal Health, LLC
13.9. Advanced Accelerator Applications
13.10. ITM Isotopen Technologien Munchen AG

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格

全球 Theranostics 市场 - 2023-2030 年

Global Theranostics Market - 2023-2030

市场概述

市场动态

用于治疗癌症的放射性核素治疗技术研究会议的增加将推动全球治疗技术市场的增长

美国 FDA 批准的癌症治疗方案越来越多，将推动全球血流显像技术市场的增长

治疗技术的高成本将阻碍全球治疗技术市场的增长

COVID-19 影响分析

俄乌冲突分析

目 录

第 1 章：研究方法与范围

第2章：定义和概述

第3章：执行摘要

第四章：动态

第 5 章：行业分析

第 6 章：COVID-19 分析

第 7 章 ：俄乌战争分析

第8章：按应用分类

第九章：按放射性同位素分类

第 10 章：按最终用户分类

第 11 章：按地区

第 12 章 ：竞争格局

第 13 章 ：公司简介